Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride

Links shared publicly online about this topic.

548
total visits

Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has signed an agreement with Tibotec Pharmaceuticals for a non-exclusive license to manufacture, market and distribute a generic version of the non-nucleoside reverse transcriptase inhibitor Rilpivirine Hydrochloride (TMC278), pending its regulatory approval for the treatment of treatment-naive HIV-1-infected adults.

View full resource at news-medical.net

Tags: HIV, AIDS, STD, Pharma, News